²é¿´: 156  |  »Ø¸´: 1
±¾Ìû²úÉú 1 ¸ö £¬µã»÷ÕâÀï½øÐв鿴

paper

½ð³æ (СÓÐÃûÆø)

[ÇóÖú] ÇóÖú ¼ìË÷ºÅ ÔÚÏßµÈ

SPARCL1 suppresses metastasis in prostate cancer

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

baiyuefei

°æÖ÷ (ÎÄѧ̩¶·)

·çÑ©

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÎÄÏ׽ܳö¹±Ï×ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
paper: ½ð±Ò+20, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2016-05-09 12:50:44
lazy½õϪ: LS-EPI+1, ¸ÐлӦÖú£¡ 2016-05-09 13:01:28
SPARCL1 suppresses metastasis in prostate cancer
×÷Õß:Xiang, YZ (Xiang, Yuzhu)[ 1,2 ] ; Qiu, QC (Qiu, Qingchao)[ 1,10,11 ] ; Jiang, M (Jiang, Ming)[ 3,4,12 ] ; Jin, RJ (Jin, Renjie)[ 3,4 ] ; Lehmann, BD (Lehmann, Brian D.)[ 6 ] ; Strand, DW (Strand, Douglas W.)[ 3,4 ] ; Jovanovic, B (Jovanovic, Bojana)[ 7 ] ; DeGraff, DJ (DeGraff, David J.)[ 3,4 ] ; Zheng, Y (Zheng, Yi)[ 1,2 ] ; Yousif, DA (Yousif, Dina A.)[ 1 ] ; Simmons, CQ (Simmons, Christine Q.)[ 1 ] ; Case, TC (Case, Thomas C.)[ 3,4 ] ; Yi, J (Yi, Jia)[ 1 ] ; Cates, JM (Cates, Justin M.)[ 8 ] ; Virostko, J (Virostko, John)[ 9 ] ; He, XS (He, Xiusheng)[ 10,11 ] ; Jin, XB (Jin, Xunbo)[ 2 ] ; Hayward, SW (Hayward, Simon W.)[ 3,4,7 ] ; Matusik, RJ (Matusik, Robert J.)[ 3,4,7 ] ; George, AL (George, Alfred L., Jr.)[ 1,5 ] ; Yi, YJ (Yi, Yajun)[ 1,5 ] ¸ü¶àÄÚÈݸüÉÙÄÚÈÝ

Òþ²Ø ResearcherID ºÍ ORCID²é¿´ ResearcherID ºÍ ORCID ×÷Õß ResearcherID ORCID ºÅ
Cates, Justin  D-5927-2014 https://orcid.org/0000-0002-7336-5196
Strand, Douglas   https://orcid.org/0000-0002-0746-927X


MOLECULAR ONCOLOGY


¾í: 7
ÆÚ: 6
Ò³: 1019-1030
DOI: 10.1016/j.molonc.2013.07.008

³ö°æÄê: DEC 2013

²é¿´ÆÚ¿¯ÐÅÏ¢

MOLECULAR ONCOLOGY  

³ö°æÉÌ ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

ISSN: 1574-7891
eISSN: 1878-0261

Ñо¿ÁìÓò Oncology



ÕªÒª
Purpose: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level.

Experimental design: Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo.

Results: SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models.

Conclusions: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

¹Ø¼ü´Ê
×÷Õ߹ؼü´Êrostate cancer; Gene expression signature; Meta-analysis; Metastasis; SPARCL1 function in vivo

KeyWords Plus:EXTRACELLULAR-MATRIX PROTEIN; MESENCHYMAL TRANSITION; MATRICELLULAR PROTEIN; SECRETED-PROTEIN; BONE METASTASIS; TUMOR-CELLS; EXPRESSION; HEVIN; STATISTICS; CARCINOMA

×÷ÕßÐÅÏ¢
ͨѶ×÷ÕßµØÖ·: Yi, YJ (ͨѶ×÷Õß) Vanderbilt Univ, Div Med Genet, 536A Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  


µØÖ·:  [ 1 ] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 2 ] Shandong Univ, Prov Hosp, Minimally Invas Urol Ctr, Jinan 250021, Peoples R China
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Shandong University  
[ 3 ] Vanderbilt Univ, Vanderbilt Prostate Canc Ctr, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 4 ] Vanderbilt Univ, Dept Urol Surg, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 5 ] Vanderbilt Univ, Inst Integrat Gen, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 6 ] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 7 ] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 8 ] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 9 ] Vanderbilt Univ, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Vanderbilt University  
[ 10 ] Univ South China, Canc Res Inst, Hengyang 421001, Peoples R China
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    University of South China  
[ 11 ] Univ South China, Human Morphol Ctr, Hengyang 421001, Peoples R China
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    University of South China  
[ 12 ] Nantong Univ, Med Res Ctr, Sch Med, Lab Nucl Receptors & Canc Res, Nantong, Peoples R China
  ÔöÇ¿×éÖ¯ÐÅÏ¢µÄÃû³Æ
    Nantong University  


µç×ÓÓʼþµØÖ·:yuzhuxiang@gmail.com; qingchao.qiu@vanderbilt.edu; ming.jiang.1@ntu.edu.cn; re-njie.jin@Vanderbilt.edu; brian.d.lehmann@Vanderbilt.edu; doug.strand@Vanderbilt.edu; bojana.jo-vanovic@Vanderbilt.edu; david.degraff@Vanderbilt.edu; milozhengyi@gmail.com; dina.a.yousif@Vanderbilt.edu; christine.simmons@Vanderbilt.Edu; tom.case@Vanderbilt.edu; jyi5@uthsc.edu; justin.m.cates@Vanderbilt.edu; jack.virostko@vanderbilt.edu; hexiusheng@hotmail.com; jin-xunbo@163.com; simon.hayward@vanderbilt.edu; robert.matusik@vanderbilt.edu; al.george@vanderbilt.edu; yajun.yi@vanderbilt.edu

»ù½ð×ÊÖúÖÂл
»ù½ð×ÊÖú»ú¹¹ ÊÚȨºÅ
Howard Temin Award from the National Cancer Institute at the National Institutes of Health  CA114033  
American Cancer Society-Institutional Research Grant  IRG-58-009-51
IRG-58-009-53  
Vanderbilt Clinical and Translational Science Awards (CTSA) from National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH)  UL1 RR024975
CRC1838  
National Cancer Institute  4R01-CA076142-14  
American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship   
²é¿´»ù½ð×ÊÖúÐÅÏ¢¹Ø±Õ»ù½ð×ÊÖúÐÅÏ¢   

Grant Support: This work was supported in part by a Howard Temin Award from the National Cancer Institute at the National Institutes of Health (CA114033 to YY), American Cancer Society-Institutional Research Grant (#IRG-58-009-51 and #IRG-58-009-53), and the Vanderbilt Clinical and Translational Science Awards (CTSA) UL1 RR024975 from National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), (CRC1838 to YY), and the National Cancer Institute (4R01-CA076142-14 to RJM). DJD was supported by the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship.

³ö°æÉÌ
ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

Àà±ð / ·ÖÀà
Ñо¿·½Ïò:Oncology

Web of Science Àà±ð:Oncology

ÎÄÏ×ÐÅÏ¢
ÎÄÏ×ÀàÐÍ:Article

ÓïÖÖ:English

Èë²ØºÅ: WOS:000328176400003

PubMed ID: 23916135

ISSN: 1574-7891

eISSN: 1878-0261

ÆäËûÐÅÏ¢
IDS ºÅ: 268NA

Web of Science ºËÐĺϼ¯ÖÐµÄ "ÒýÓõIJο¼ÎÄÏ×": 50

Web of Science ºËÐĺϼ¯ÖÐµÄ "±»ÒýƵ´Î": 2

Ó°ÏìÒò×Ó 5.331  5.669  
2014  5 Äê  


JCR® Àà±ð Àà±ðÖеÄÅÅÐò JCR ·ÖÇø
ONCOLOGY  28/211  Q1


Êý¾ÝÀ´×ÔµÚ 2014 °æ Journal Citation Reports®
2Â¥2016-05-09 12:42:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ paper µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +3 @taotao 2026-03-21 3/150 2026-03-21 18:11 by WTUChen
[¿¼ÑÐ] 26¿¼ÑÐÒ»Ö¾Ô¸ÖйúʯÓÍ´óѧ(»ª¶«)305·ÖÇóµ÷¼Á +6 ¼ÎÄêÐÂ³Ì 2026-03-15 6/300 2026-03-21 17:07 by Dream007008
[¿¼ÑÐ] 266Çóµ÷¼Á +3 ÍÛºôºßºôºß 2026-03-20 3/150 2026-03-21 16:46 by barlinike
[¿¼ÑÐ] 0805²ÄÁÏ320Çóµ÷¼Á +3 ÉÎïÓï 2026-03-20 3/150 2026-03-21 15:46 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 22 350 ±¾¿Æ985Çóµ÷¼Á£¬ÇóÀϵÇÊÕÁô +3 ÀîéóÄÐ003 2026-03-20 3/150 2026-03-21 13:28 by ²«»÷518
[¿¼ÑÐ] ²ÄÁÏѧѧ˶080502 337Çóµ÷¼Á-Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ +4 ˳˳˳mr 2026-03-18 5/250 2026-03-21 10:22 by luoyongfeng
[¿¼ÑÐ] Çóµ÷¼Á +6 Mqqqqqq 2026-03-19 6/300 2026-03-21 08:04 by JourneyLucky
[¿¼ÑÐ] 332Çóµ÷¼Á +4 ydfyh 2026-03-17 4/200 2026-03-21 02:20 by JourneyLucky
[¿¼ÑÐ] 304Çóµ÷¼Á +7 ˾¿Õ. 2026-03-18 7/350 2026-03-20 23:08 by JourneyLucky
[¿¼ÑÐ] 289Çóµ÷¼Á +6 »³èªÎÕè¤l 2026-03-20 6/300 2026-03-20 20:30 by ѧԱ8dgXkO
[¿¼ÑÐ] 261ÇóBÇøµ÷¼Á£¬¿ÆÑо­Àú·á¸» +3 Å£Ä̺Üæ 2026-03-20 4/200 2026-03-20 19:34 by JourneyLucky
[¿¼ÑÐ] 0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥ +8 sllhht 2026-03-19 9/450 2026-03-20 14:25 by ÎÞи¿É»÷111
[¿¼ÑÐ] 328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑо­Àú +4 ÉúÎ﹤³Ìµ÷¼Á 2026-03-16 12/600 2026-03-19 11:10 by ÉúÎ﹤³Ìµ÷¼Á
[¿¼ÑÐ] 311Çóµ÷¼Á +6 26ÑÐ0 2026-03-15 6/300 2026-03-18 14:43 by haxia
[¿¼ÑÐ] 0703»¯Ñ§336·ÖÇóµ÷¼Á +6 zbzihdhd 2026-03-15 7/350 2026-03-18 09:53 by zhukairuo
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] 293Çóµ÷¼Á +11 zjlµÄºÅ 2026-03-16 16/800 2026-03-18 08:10 by zhukairuo
[¿¼²©] 26²©Ê¿ÉêÇë +3 1042136743 2026-03-17 3/150 2026-03-17 23:30 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] 275Çóµ÷¼Á +4 Ì«Ñô»¨ÌìÌ쿪ÐÄ 2026-03-16 4/200 2026-03-17 10:53 by ¹¦·ò·è¿ñ
[¿¼ÑÐ] »úеר˶325£¬Ñ°ÕÒµ÷¼ÁԺУ +3 y9999 2026-03-15 5/250 2026-03-16 19:58 by y9999
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û